Companies that once boasted they were LGBTQ+ friendly are jettisoning their support to protect their bottom line.
The Embolden trial builds on positive interim data from the Phase 1/2 trial of NGN-401, which demonstrated multidomain, durable gains with continued developmental milestone acquisitions as of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results